Canada · Coverage
Renewing GLP-1 coverage in Canada: public plans and private insurers
Applies to: Canada
By Joshua Nichvolodoff · Fact-checked against sources November 2, 2026 · Next review due January 31, 2027
Clinical review: not yet reviewed by a clinician. How review works · Editorial policy
Whether your GLP-1 coverage needs renewing in Canada depends on who pays: a provincial plan or a private insurer. Here is what BC and Ontario publish, what two private insurers' forms ask for at renewal, and what to gather. It can't tell you whether you qualify — only your plan decides that.
British Columbia
Special Authority requests are submitted by prescribers, not patients; the current turnaround for faxed requests is 4 weeks, and coverage is not backdated[5]. Semaglutide is covered for type 2 diabetes after inadequate control on metformin, with an indefinite approval period — so there is no periodic renewal for that coverage[1][6].
Ontario
Ozempic became a Limited Use benefit on January 31, 2024, for adults with type 2 diabetes, with an indefinite authorization period — no Limited Use renewal is required[2]. For drugs outside the formulary, only a physician or nurse practitioner can apply to the Exceptional Access Program, and how long coverage lasts depends on the drug and condition[7].
Private insurers
Express Scripts Canada's Wegovy form asks, for an adult renewal, for documented loss of 5% or more of body weight, with baseline and current weights and dates[3]. Desjardins' form for obesity medications asks, at renewal, for weight, height and BMI at the start of treatment and from the most recent visit, and confirmation of a reduced-calorie diet and physical activity; continuing beyond the authorized period needs a new request[4]. Canada Life added Wegovy to its prior authorization program in 2023[8]. Always use your own insurer's current form, unaltered.
If a request or renewal is declined, questions to ask your insurer, plan or prescriber's office:
- Which criterion wasn't met, or which document or measurement was missing?
- Can my prescriber send more information or a new request, and is there a deadline?
- Is there a review or appeal process, and how do I start it?
- Is a different form, program or exception available for my situation?
Asking doesn't change the criteria or promise a different decision. It helps you and your prescriber see what's missing.
What to gather before your authorization ends
- Your approval letter or notice: the drug, the authorized period, and any reference number.
- Your starting weight, height and the date; your most recent weight and the date.
- Your insurer's current prior authorization form (linked from its website or your plan booklet).
- The date to contact your prescriber — renewals are completed by your prescriber's office.
- Prior authorization endsfrom your plan's approval letter
- Prescription expiresfrom your pharmacy label or pharmacist
- Next refill duefrom your own supply
- Appeal deadlineonly if you were denied — from the denial letter
To keep track of these in one place, use the coverage renewal brief — a blank checklist that keeps the dates apart and prints a summary for your prescriber. It stays in your browser.
General information, not legal, insurance or medical advice. Criteria and forms change; your plan decides.
Sources
- Limited coverage criteria — semaglutide. Province of British Columbia (PharmaCare), April 21, 2026. https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/pharmacare/programs/limited-coverage-drug-program/limited-coverage-drugs-semaglutide. Accessed November 2, 2026. Back to the text
- Executive Officer notice: update to Ozempic listing — change in status to Limited Use benefit. Ontario Ministry of Health, January 26, 2024. https://www.ontario.ca/files/2024-01/moh-executive-officer-notice-en-2024-01-26.pdf. Accessed November 2, 2026. Back to the text
- Prior authorization request — WEGOVY (semaglutide) (blank form). Express Scripts Canada, July 28, 2026. https://www.express-scripts.ca/sites/default/files/paf/en/WEGOVY%20(semaglutide)%20-%20EN.pdf. Accessed November 2, 2026. Back to the text
- Prior authorization request — Contrave, Saxenda, Wegovy, Xenical, Zepbound (form 12607E, 2026-09) (blank form). Desjardins Insurance, September 2026. https://www.desjardins.com/content/dam/pdf/en/personal/insurance/health-dental/drug-prior-authorization/12607E.pdf. Accessed November 2, 2026. Back to the text
- Special Authority Request — Semaglutide for Diabetes (HLTH 5826). BC Ministry of Health, February 13, 2026. https://www2.gov.bc.ca/assets/gov/health/forms/5826fil.pdf. Accessed November 2, 2026. Back to the text
- Faire une demande au Programme d’accès exceptionnel (Exceptional Access Program). Government of Ontario, October 18, 2023. https://www.ontario.ca/fr/page/faire-une-demande-au-programme-dacces-exceptionnel. Accessed November 2, 2026. Back to the text
- Updates to Ozempic and Rybelsus (semaglutide) coverage coming soon. Canada Life, September 12, 2023. https://www.canadalife.com/content/dam/group-customer/Semaglutide-coverage-updates-sponsors.pdf. Accessed November 2, 2026. Back to the text
Figures marked “as reported” are historical: they show what the source said on that date, not today's price or rule.
Changes to this page
- — First published.
Substantive corrections are also logged at corrections.